Gilead Sciences, Inc. is calling for more transparency on how the National Health Service (NHS) in England arrived at figures on the cost of delivering CAR-T therapies to patients. The company's Gordon Lundie has warned that if the health technology appraisal body NICE continues to accept these costs, it will be impossible for companies selling CAR-T therapies to offer a price that NICE regards as cost effective.
In July, NICE issued draft guidance rejecting Kite’s CAR-T therapy Yescarta (axicabtagene ciloleucel) for treating adult patients with relapsed...